摘要
埃博拉病毒自1976年被确认以来,已在10个不同国家造成26起疫情,使其成为最致命的新兴病毒病原体之一。2014-16年西非最近爆发的疫情是迄今为止最致命的一次疫情,在28616例确诊病例中死亡11310人。目前,还没有FDA批准的治疗方法或疫苗来治疗埃博拉病毒感染。有效疫苗的缓慢发展加上以往疫情的严重程度,强调有必要加速研究了解病毒的生命周期,以及开发暴露后治疗的疗法。在这里,我们总结了埃博拉病毒复制周期的主要发现和治疗这种破坏性疾病的治疗方法。本综述的重点是小分子抑制剂。
关键词: 埃博拉病毒,病毒病原体,埃博拉病毒属,埃博拉病毒进入机制,转录和复制机制,马尔堡病毒。
Current Medicinal Chemistry
Title:Development of Potential Small Molecule Therapeutics for Treatment of Ebola Virus Disease
Volume: 25 Issue: 38
关键词: 埃博拉病毒,病毒病原体,埃博拉病毒属,埃博拉病毒进入机制,转录和复制机制,马尔堡病毒。
摘要: Ebola virus has caused 26 outbreaks in 10 different countries since its identification in 1976, making it one of the deadliest emerging viral pathogens. The most recent outbreak in West Africa from 2014-16 was the deadliest yet and culminated in 11,310 deaths out of 28,616 confirmed cases. Currently, there are no FDA-approved therapeutics or vaccines to treat Ebola virus infections. The slow development of effective vaccines combined with the severity of past outbreaks emphasizes the need to accelerate research into understanding the virus lifecycle and the development of therapeutics for post exposure treatment. Here we present a summary of the major findings on the Ebola virus replication cycle and the therapeutic approaches explored to treat this devastating disease. The major focus of this review is on small molecule inhibitors.
Export Options
About this article
Cite this article as:
Development of Potential Small Molecule Therapeutics for Treatment of Ebola Virus Disease, Current Medicinal Chemistry 2018; 25 (38) . https://dx.doi.org/10.2174/0929867324666171010141416
DOI https://dx.doi.org/10.2174/0929867324666171010141416 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements